Aβ immunization worsens iron deposits in the choroid plexus and cerebral microbleeds

• Published in: Neurobiology of aging Vol. 34; no. 11; pp. 2613 - 2622
• Main Authors: Joseph-Mathurin, Nelly, Dorieux, Olène, Trouche, Stéphanie G., Boutajangout, Allal, Kraska, Audrey, Fontès, Pascaline, Verdier, Jean-Michel, Sigurdsson, Einar M., Mestre-Francés, Nadine, Dhenain, Marc
• Format: Journal Article
• Language: English
• Published: 22.06.2013
• ISSN: 0197-4580; 1558-1497
• DOI: 10.1016/j.neurobiolaging.2013.05.013

Anti-Aβ immunotherapy provides potential benefits in Alzheimer’s disease patients. Nevertheless, strategies based on Aβ1-42 peptide induced encephalomyelitis and possible microhemorrhages. These outcomes were not expected from studies performed in rodents. It is critical to determine if other animal models better predict side effects of immunotherapies. Mouse lemur primates can develop amyloidosis with aging. Here we used old lemurs to study immunotherapy based on Aβ1-42 or Aβ-derivative (K6Aβ1-30). We followed anti-Aβ40 IgG and IgM responses as well as Aβ levels in plasma. In-vivo magnetic resonance imaging and histology were used to evaluate amyloidosis, neuroinflammation, vasogenic edema, microhemorrhages, and brain iron deposits. The animals responded mainly to the Aβ1-42 immunogen. This treatment induced immune response and increased Aβ levels in plasma but also microhemorrhages and iron deposits in the choroid plexus. A complementary study of untreated lemurs showed iron accumulation in the choroid plexus with normal aging. Worsening of iron accumulation is thus a potential side effect of Aβ-immunization at prodromal stages of Alzheimer’s disease, and should be monitored in clinical trials.